Compared with the clinically progressive myeloma precursor condition, the clinically stable myeloma precursor condition was associated with late initiation of the first clonal copy number alteration in patients’ life and absence or lower number of mutations in driver genes (genes involved in MAPK and NF-κB pathways, TP53), aneuploidy (gain of 1q, deletion of 6q, gain of 8q24, deletion of 8p, and deletion of 16q), templated insertions, chromothripsis, and APOBEC-associated mutational activity. This evidence concerns the gene TP53 and plasma cell myeloma.